Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria (DIAMOND)
A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial
Sponsor: AstraZeneca
Listed as NCT03190694, this PHASE2 trial focuses on Chronic Kidney Diseases and Proteinuria and remains completed. Sponsored by AstraZeneca, it has been updated 8 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Nov 2018 — Oct 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Aug 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Hiddo Lambers Heerspink
For direct contact, visit the study record on ClinicalTrials.gov .